Loading
Life sciences · Journal article
Scientific Reports · September 16, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Cancer remains a leading cause of mortality globally, while hypertension is the primary contributor to cardiovascular disease and premature death. These conditions frequently coexist; hypertension may precede cancer due to shared risk factors or arise during or after cancer treatment, partly as a result of the hypertensive effects of antineoplastic therapies. As cancer survival rates improve, effective management of comorbid hypertension has become increasingly important. In this study we analyzed data from the Surveillance, Epidemiology, and End Results (SEER) database, which includes 17 registries and cover approximately 34.6% of the U.S. population, this study evaluated hypertension-related mortality among cancer patients diagnosed between 2000 and 2021. Causes of death were stratified by demographic, clinical, treatment, and cancer-specific characteristics. Standardized mortality ratios (SMRs) with 95% confidence intervals (CIs) were calculated across survival intervals. Among 6,891,191 patients with malignant disease, 17,780 deaths (0.26%) were attributed to hypertension. Hypertension-related mortality was 24% higher than in the general population (SMR 1.24, 95% CI 1.22–1.26), with the greatest excess observed within the first year after diagnosis (SMR 2.04, 95% CI 1.97–2.11). Elevated risk was identified among patients younger than 40 years, racial minorities, unmarried individuals, those with regional or distant disease, and those who did not receive surgery, radiotherapy, or chemotherapy, particularly during the first year after diagnosis. No improvement in hypertension mortality was observed during 2010–2021, and females exhibited a slightly higher risk than males. SMRs did not decrease over time, and females exhibited a slightly higher risk than males. These findings support the consideration of early and sustained onco-hypertension management and coordinated care among oncologists, cardiologists, and primary care physicians. Further research examining patient-level risk factors, comorbidities, treatment strategies, and socioeconomic determinants is essential to improve survival outcomes among cancer survivors.